Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
96% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. CPRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CPRX' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
94% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2145.51 vs. CPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 19.65
M-Score: -3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -43.35
CPRX's ROE (%) is ranked lower than
87% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. CPRX: -43.35 )
Ranked among companies with meaningful ROE (%) only.
CPRX' s 10-Year ROE (%) Range
Min: -1906.67   Max: -22.89
Current: -43.35

-1906.67
-22.89
ROA (%) -36.56
CPRX's ROA (%) is ranked lower than
89% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. CPRX: -36.56 )
Ranked among companies with meaningful ROA (%) only.
CPRX' s 10-Year ROA (%) Range
Min: -766.07   Max: -22.19
Current: -36.56

-766.07
-22.19
ROC (Joel Greenblatt) (%) -1524.09
CPRX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. CPRX: -1524.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -108600   Max: -485.88
Current: -1524.09

-108600
-485.88
EBITDA Growth (3Y)(%) -6.30
CPRX's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. CPRX: -6.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CPRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 42
Current: -6.3

0
42
EPS Growth (3Y)(%) -6.10
CPRX's EPS Growth (3Y)(%) is ranked lower than
64% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. CPRX: -6.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CPRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.7   Max: 40.8
Current: -6.1

-33.7
40.8
» CPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CPRX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q3 2014

CPRX Guru Trades in Q3 2014

Jim Simons 196,500 sh (New)
» More
Q4 2014

CPRX Guru Trades in Q4 2014

Steven Cohen 3,500,000 sh (New)
Steven Cohen 3,500,000 sh (unchged)
Steven Cohen 3,500,000 sh (unchged)
Jim Simons Sold Out
» More
Q1 2015

CPRX Guru Trades in Q1 2015

Jim Simons 21,227 sh (New)
Steven Cohen 6,568,000 sh (+87.66%)
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
CPRX's P/B is ranked lower than
63% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. CPRX: 4.80 )
Ranked among companies with meaningful P/B only.
CPRX' s 10-Year P/B Range
Min: 2.33   Max: 26.33
Current: 4.8

2.33
26.33
Current Ratio 12.99
CPRX's Current Ratio is ranked higher than
92% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. CPRX: 12.99 )
Ranked among companies with meaningful Current Ratio only.
CPRX' s 10-Year Current Ratio Range
Min: 0.75   Max: 54.56
Current: 12.99

0.75
54.56
Quick Ratio 12.99
CPRX's Quick Ratio is ranked higher than
93% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. CPRX: 12.99 )
Ranked among companies with meaningful Quick Ratio only.
CPRX' s 10-Year Quick Ratio Range
Min: 0.75   Max: 54.56
Current: 12.99

0.75
54.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.60
CPRX's Price/Net Cash is ranked higher than
72% of the 302 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.30 vs. CPRX: 5.60 )
Ranked among companies with meaningful Price/Net Cash only.
CPRX' s 10-Year Price/Net Cash Range
Min: 1.36   Max: 18.63
Current: 5.6

1.36
18.63
Price/Net Current Asset Value 5.40
CPRX's Price/Net Current Asset Value is ranked higher than
74% of the 405 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.00 vs. CPRX: 5.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.24   Max: 10.09
Current: 5.4

1.24
10.09
Price/Tangible Book 4.90
CPRX's Price/Tangible Book is ranked lower than
52% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. CPRX: 4.90 )
Ranked among companies with meaningful Price/Tangible Book only.
CPRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 10.09
Current: 4.9

1.24
10.09
Price/DCF (Projected) 33.30
CPRX's Price/DCF (Projected) is ranked lower than
93% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. CPRX: 33.30 )
Ranked among companies with meaningful Price/DCF (Projected) only.
CPRX' s 10-Year Price/DCF (Projected) Range
Min: 15   Max: 36.08
Current: 33.3

15
36.08
Earnings Yield (Greenblatt) -6.20
CPRX's Earnings Yield (Greenblatt) is ranked lower than
81% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. CPRX: -6.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -7.4   Max: 0
Current: -6.2

-7.4
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CN2.Germany,
Catalyst Pharmaceutical Partners Inc was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. In October 2012, the Company licensed the North American rights to Firdapse(tm), a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). CPP-115 is in the early stages of developing CPP-115, a GABA aminotransferase inhibitor that, based on its pre-clinical studies to date, it believe is a more potent form of vigabatrin, but may have fewer side effects than those associated with vigabatrin. CPP-109 was evaluated for the treatment of cocaine addiction. An academic investigator proof-of-concept study evaluating the use of CPP-109 for the treatment of Tourette syndrome is currently ongoing. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent Public O Feb 17 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX Jan 18 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, CPRX, BRT Jan 12 2015 
Largest Insider Buys of the Week Oct 25 2013 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 28 2015
Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer May 28 2015
Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer May 28 2015
CATALYST PHARMACEUTICALS, INC. Financials May 27 2015
Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference May 27 2015
Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference May 27 2015
CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 22 2015
10-Q for Catalyst Pharmaceutical Partners, Inc. May 13 2015
Catalyst Pharmaceutical's Q1 Loss Narrower than Expected - Analyst Blog May 12 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... May 12 2015
Catalyst Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Corporate... May 11 2015
Catalyst Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Corporate... May 11 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Q1 2015 Catalyst Pharmaceutical Partners Inc Earnings Release - After Market Close May 11 2015
Can Catalyst Pharmaceutical Surprise this Earnings Season? - Analyst Blog May 08 2015
10-K for Catalyst Pharmaceutical Partners, Inc. May 05 2015
Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference... May 04 2015
Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference... May 04 2015
Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results Apr 24 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Apr 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK